Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 di ... Read more
Novo Nordisk A/S: Saxenda® demonstrated improvements in BMI and body weight in a ... Read more
Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 di ... Read more
Novo Nordisk A/S - Share repurchase programme ... Read more
Resolutions from the Annual General Meeting of Novo Nordisk A/S ... Read more
Novo Nordisk A/S – Share repurchase programme ... Read more
If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.
31 March - During the global coronavirus outbreak, Novo Nordisk’s key priority is to safeguard the continued supply of our lifesaving medicines to patients.
The situation is continually evolving, but currently we are not experiencing any supply constraints. We are well prepared for situations like this and have an inventory policy that serves long-term supply. This is important since our medicines are needed every day by patients all over the world.
Updates on Novo Nordisk's latest contributions and initiatives
20 November - Novo Nordisk and UNICEF have announced a new partnership to help prevent childhood overweight and obesity worldwide with an initial focus on interventions in Latin America and the Caribbean.
Under this partnership, the United Nations children’s agency and the global healthcare company will combine efforts to enhance knowledge and awareness on how to prevent overweight and obesity and address their root causes. The partnership will initially cover a period of three years.
“There is no doubt that childhood overweight and obesity is a public health crisis that requires immediate attention. Childhood overweight and obesity is more than an individual choice, this is everybody’s business. Together with UNICEF, we hope to help millions of children lead healthy lives and at the same time ease the burden of obesity to society,” said Novo Nordisk President and CEO Lars Fruergaard Jørgensen.
Read the full press release on the partnership
What if medicines injected by millions could be delivered in tablets?
After almost 100 years of delivering injectable therapies, Novo
Nordisk’s R&D team is finding answers to this enduring question.
Chief Science Officer Mads Krogsgaard Thomsen is leading the way and
he reflects on the magnitude of the scientific challenge and the
progress made in his laboratories.
Novo Nordisk intends to achieve the target to use only renewable electricity in
its global production facilities by 2020. The announcement on 30
April followed a new investment in a 672-acre solar panel
installation, roughly the size of 500 football fields, in North
Carolina, US, which will provide power to Novo Nordisk’s entire US
operations from early 2020. Novo Nordisk is the first pharmaceutical
company in
RE100
to use only renewable electricity
in production. RE100 is a collaborative, global initiative of
businesses committed to using 100% renewable electricity.
Read more about Circular
for Zero and download
the full press release on the environmental ambitions
The International Committee of the Red Cross (ICRC), the Danish Red
Cross (DRC) and Novo Nordisk have partnered to tackle the growing
issue of chronic diseases that affect millions of people living in
humanitarian crises around the world. Focus will be on ensuring
efficient supply of low-cost human insulin in vials to Red Cross
globally; support for ICRC’s and DRC’s health programmes; 2-3 projects
to provide care to people with hypertension and diabetes in
humanitarian crises to be conducted within three years.
Read CEO Lars Fruergaard's reflections and more about the partnership
6 May - first quarter
6 August - first 6 months
30 October - first 9 months
When Pâris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years.
